Induced pluripotent stem cell (iPSC)-derived cardiovascular progenitor cells represent a suitable autologous cell source for myocardial regeneration as they have the capability to form myocardial cells and to contribute to revascularization. As a first proof of concept we evaluated the potential of a murine iPSC-derived cardiovascular progenitor population, which expresses the surface marker foetal liver kinase-1 (Flk-1), to restore myocardial tissue and improve cardiac function after acute myocardial infarction (MI) in mice. --
Methods and results

iPSC-derived
Introduction
Pluripotent stem cells have the ability to differentiate into cell types of all three germ layers, 1 including cardiac and vascular derivatives.
It is still a matter of debate whether more or less mature stem cellderived progenies represent the most suitable cell source for cardiac repair. 2 Premature embryonic stem cell (ESC)-derived progenitors with the potential to differentiate into both cardiac and † These authors contributed equally vascular cell types have been identified as Flk-1 pos , Isl1 pos , Mesp1 pos , or Nkx2.5 pos populations. 3 -11 Recently, reprogramming of somatic cells into a pluripotent state was demonstrated. 12 -14 These induced pluripotent stem cells (iPSCs) are essentially identical to ESCs, but offer the possibility to generate autologous patient-specific pluripotent stem cells. It has been shown that murine and human iPSCs are able to form multipotent cardiovascular progenitors and mature cardiomyocytes similar to those derived from ESCs. 15 -20 In contrast to cardiomyocytes, cardiovascular progenitors might not only restore myocardial tissue, but would also contribute to revascularization. In addition, progenitors may be more robust to survive in the hostile graft environment. 2 However, complete removal of contaminating pluripotent cells with teratogenic potential from cell suspensions containing cardiovascular progenitor cells is challenging.
For the first time we evaluated the intramyocardial transplantation of murine iPSC-derived foetal liver kinase-1-positive (Flk-1 pos ) cardiovascular progenitors. As Flk-1 is expressed on the cell surface, selection can be achieved without genetic manipulations. The iPSC-derived Flk-1 pos and Flk-1 neg cell fractions were both analysed for their potential to give rise to cardiomyocytes, smooth muscle, and endothelial cells in vitro and in vivo. Safety concerns regarding teratoma induction were addressed by taking advantage of the Oct4-promoter-dependent expression of eGFP to deplete contaminating undifferentiated cells prior to cell injection. The ability of iPSC-derived Flk-1 pos progenitors to form vascularized myocardial tissue and to improve heart function was assessed in a mouse model of acute myocardial infarction (MI).
Methods
Generation of a transgenic murine iPSC clone
Embryonic fibroblasts from octamer binding factor 4 (Oct4)-enhanced green fluorescent protein (eGFP) expressing OG2 mice 21 were reprogrammed by the overexpression of Oct4, Sox2, c-Myc, and Klf4. 12 To trace transplanted cells, iPSC clones were further transduced by a lentiviral vector mediating the ubiquitous nuclear expression of the fluorescent protein Venus-a more stable variant of yellow fluorescent protein (YFP). 22 Studies were performed on a selected subclone termed B4. Differentiation into Flk-1 pos cells is described in detail in the online Supplementary material.
Animal care
Surgery and animal care were provided following the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, volume 25, no 28, revised 1996) and in accordance with institutional and federal regulations. 
Myocardial infarction model
Conductance catheter analysis
On Day 14, conductance catheter (CC) analysis was performed according to standard protocols (see online Supplementary material). Pressure -volume loops were recorded in steady state to acquire volumetric and functional parameters. Afterwards, animals were sacrificed for histological evaluation.
Histology and immunostaining
Hearts were processed in standard fashion and histological morphometry, and immunostaining was performed as described in the online Supplementary material. iPSC-derived grafts were detected by their intrinsic nuclear Venus (nucVenus) expression. Graft size was measured using a pixel-based approach. Data were obtained by computer-assisted morphometry (Image J 1.40 g, NIH, USA).
Statistics
GraphPad Prism 5.03 was used for statistical analysis. If not stated otherwise, data are given as mean + SEM. Continuous variables were analysed with either paired or unpaired Student's t-test or with one-way ANOVA followed by Tukey's multiple comparison test, as appropriate. Linear regression analysis was performed to correlate continuous data. Differences were considered significant at P , 0.05. All reported P-values are two-sided.
Results
The pluripotent iPSC clone shows cardiovascular differentiation potential in vitro
Pluripotency of the transgenic iPSC clone B4 was demonstrated by the expression of pluripotency markers and its ability to form teratomas (see Supplementary material online, Figures S1 and S2). For cardiovascular differentiation in vitro, iPSCs were differentiated using an embryoid body (EB)-based protocol (see Supplementary material online). On Day 17 of differentiation, 77.7 + 12.4% of iPSC-derived EBs (76 + 17 EBs per experiment, n ¼ 3) had spontaneously contracting areas (see Supplementary material online, Figure S2 ), indicating efficient cardiac differentiation. In addition, EB-derived differentiation cultures contained cells which were immunopositive for the cardiomyocyte markers cardiac troponin T (cTnT) and connexin 43 (Cx43). Cells expressing the endothelial marker Cd31 and the smooth muscle marker a-smooth muscle actin (a-SMA) were also present (see Supplementary material online, Figure S2 ). and depleted in the Flk-1 neg population (2.7 + 2.0%, n ¼ 24; Figure 1H ). Additional depletion of Oct4-eGFP pos cells markedly reduced contaminating pluripotent Oct4-eGFP pos cells from 15.5 + 13.0% (unsorted, n ¼ 10) to 3.8 + 3.3% in the Flk-1 neg population (n ¼ 23) and to 0.6 + 0.6% in the Flk-1 pos population, (n ¼ 12; Figure 1I ). These results correlated with the percentage of colonies formed by Oct4 immunopositive cells following cultivation of the selected populations in pluripotency-supporting medium (see Supplementary material online, Figure S3 ). 
Intramyocardial transplantation of Flk-1 progenitors prevents adverse remodelling and improves cardiac function
Compared with infarct sizes determined by MRI on Day 2 post MI, Masson's Trichrome staining on Day 14 showed enlarged infarcts in the PBS group as a sign for adverse remodelling. In contrast, infarct size decreased in cell-treated animals ( Figure 3B) . On an average, Flk-1 pos cell grafts were considerably larger than Flk-1 neg cell grafts and led to improved LV wall thickening ( Figures 3C and 4) . Flk-1 progenitor cells from murine iPSCs cells resulted in an improved area of viable myocardium within the infarct zone ( Figure 3D ). However, beneficial effects on myocardial remodelling were more pronounced in Flk-1 pos cell-treated animals as opposed to the Flk-1 neg group ( Figures 3C and 4) . Table S2 and Figure S6 Table   S2 and Figures S6 and S7 ).
LAD-ligation resulted in a significant reduction in LV function and in a volume overload in ischaemic controls (PBS) compared with sham-operated animals (see Supplementary material online,
Flk-1 progenitor cells form cardiovascular cell types in vivo
The YFP variant Venus tagged with a nuclear location signal enabled clear-cut identification of donor cells after transplantation into the highly autofluorescent host myocardium ( Figure 6 ). online, Figure S8 ). Those Flk-1 and Cd31 immunopositive cells formed vessels that were connected to the host's vasculature as indicated by the presence of erythrocytes within the donorderived vascular structures ( Figure 6I and O, red arrows). Small numbers of a-SMA immunopositive cells in Flk-1 pos and
Flk-1 neg grafts could also be detected (data not shown).
In correlation with the in vitro data (see Supplementary material online, Figure S3 ), restricted areas of Oct4-eGFP pos undifferentiated iPSCs were present especially in grafts of transplanted Flk-1 neg cells ( Figure 6 , white arrows).
Discussion
The generation of iPSCs is considered as a breakthrough in the development of novel cellular therapies. A series of studies demonstrated that iPSCs form functional cardiovascular cell lineages with similar efficiency as ESCs. 15 -20 So far, studies underpinning their usefulness in cardiac cell therapy are rare. 17, 20 Various ESC-and iPSC-derived cardiovascular progenitor populations characterized by the expression of different molecular markers have been described. 3 -11,17 -20 Flk-1, as a surface molecule, allows for selection of those progenitor cells without genetic manipulation and the general cardiovascular potential of iPSCderived Flk-1 pos cells in vitro has been reported recently. 18, 19 In the present study, we evaluated the capacity of murine iPSCderived Flk-1 pos cells to form vascularized heart tissue following acute MI in mice and to restore heart function. ). However, we were not able to identify a structural organization and alignment as well as a typical cross-striation pattern of donor cardiomyocytes within iPSC-derived grafts. In our opinion, these cells represent an early and immature cardiomyocyte phenotype. However, despite the lack of well-aligned mature donor cardiomyocytes, we observed a beneficial remodelling and improved ventricular function compared with placebo treatment. This finding is most likely the result of a multimodal effect based on geometric LV wall stabilization and paracrine mechanisms rather than attributed to a contractile 'de novo myocardium'. 23 Positive effects were more pronounced after treatment with Flk-1 pos cells, which can be explained by the formation of larger grafts and enhanced neovascularization with donorderived vessels that appeared to be connected to the recipient's circulation ( Figures 4 and 6I and O, see Supplementary material online, Figure S8 ). As a limitation of this study, we did not extend our observation period to .2 weeks. Additional long-term studies have to be done to investigate whether the proliferative potential of Flk-1 pos cardiovascular progenitors is advantageous to achieve larger graft sizes or rather induces tumour-like growth, which hinders structured organization of mature myocardium. The expansive growth of Flk-1 pos cells within 2 weeks following transplantation might argue against a direct intramyocardial injection. We believe that these cells are most suitable for tissue engineering approaches that will allow for directed differentiation as well as control of proliferation and maturation in vitro before transplantation.
In conclusion, the FACS-sorting of iPSCs using the cell surface marker Flk-1 is a feasible technique to provide sufficient amounts of cardiovascular progenitor cells. We identified iPSC-derived 
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